Return to MD Anderson Cancer Center

Return to Department of Thoracic and Cardiovascular Surgery

What's New
Faculty & Staff
  Rajagopal Ramesh, Ph.D.
    Curriculum Vitae
Education
Specific Diseases
Videos
Research
F.A.Q.
Glossary of Terms
Web Links
Thoracic Center
Contact Information

 

  

Curriculum Vitae - Rajagopal Ramesh, Ph.D.

Academic and Professional Appointments:

2001-present, Assistant Professor, Department of Thoracic and Cardiovascular Surgery, UT M. D. Anderson Cancer Center, Houston, Texas

1998-2001, Research Associate, Department of Thoracic and Cardiovascular Surgery, UT M. D. Anderson Cancer Center, Houston, Texas

1997-1998, Research Instructor, Department of Surgery, Louisiana State University Medical Center, New Orleans, Louisiana

1996-1997, Research Associate, Department of Pathology, Tulane University School of Medicine, New Orleans, Louisiana

Back to Top

Editorships and Editorial Board Memberships:

Adhoc reviews:

Back to Top

Lectureships and Visiting Professorships:

Back to Top

Honors and Awards:

  • Young Investigator in Medical Sciences Award, Indian National Science Academy, New Delhi, India, 1993
  • Searle Award, Best Oral Paper, Annual Conference of Indian Society of Gastroenterology, 1992
  • Best Paper in Basic Sciences Research, Annual Conference of the Indian Association for the Study of the Liver, 1991
  • Senior Research Fellowship, Council of Scientific and Industrial Research, 1991-1993


Back to Top

Society Memberships and Offices Held:

  • Member, American Society for Gene Therapy
  • Member, American Association of Cancer Research
  • Member, American Society for Biochemistry and Molecular Biology
  • Member, American Society of Microbiology

Bibliography:

Published and accepted articles in refereed journals

Published and accepted invited journal articles

Published and accepted book chapters

Back to Top

Institutional Service Responsibilities and Other Duties:

Back to Top

Formal Teaching Experience:

Courses taught:

Back to Top

Invitations to National or International Conferences:

  1. Screening of sera from HCC patients infected with HBV in India, 5th Annual Conference of the Indian Association of Pathologist and Microbiologist, Delhi Chapter, India, 1990.
  2. Incidence of duck hepatitis B virus infection in India, 5th Annual Conference of the Indian Association Pathologist and Microbiologist, Delhi Chapter, India, 1990.
  3. Detection of hepatitis B virus DNA in hepatocellular carcinoma by polymerase chain reaction, 32nd Conference of the Indian National Association for the Study of Liver, Trivandrum, India, 1991.
  4. Detection of HBV and HCV in hepatocellular carcinoma patients in India, The 5th International Symposium on Viral Hepatitis, Madrid, Spain, 1992.
  5. Effect of Phyllanthus amarus on serum DNA in chronic duck hepatitis B virus (DHBV) infection, The 5th International Symposium on Viral Hepatitis, Madrid, Spain, 1992.
  6. Detection and sub-genomic analysis of hepatitis B virus DNA in hepatocellular carcinoma using polymerase chain reaction. 33rd National Conference of the Indian Society of Gastroenterology and Endoscopy; 1992.
  7. Importance of transactivators in hepatitis B virus associated hepatocellular carcinoma, The IX Asian Pacific Congress of Gastroenterology and VI Asian Pacific Congress of Digestive Endoscopy, Bangkok, Thailand, 1992.
  8. Mapping of hepatitis B virus genome in hepatocellular carcinoma using polymerase chain reaction and potential transactivation by the frequently detected fragment, The 8th. International Symposium on Viral Hepatitis and Liver Diseases (Triennial Congress), Tokyo, Japan, 1993.
  9. Identification and analysis of polymerase chain reaction (PCR) amplified sub-genomic fragments of hepatitis B virus in hepatocellular carcinoma, Indo-French Symposium on "Trends in Cancer Research", Cancer Research Institute, Bombay, India, 1993.
  10. Suicide genes as an anti-cancer strategy,1st European Conference on Gene Therapy of Cancer. London, U.K., 1994.
  11. Gene Therapy: A chemoimmunotherapeutic approach using HSV-TK cells. Society for Biological Therapy, 1994.
  12. Suicide genes as an anti-cancer strategy, 3rd International Symposium on Gene Therapy, San Diego, California, Nov.11-13, 1994.
  13. 19th International Conference on role of Blood Bank in Gene Therapy, Netherlands, 1994.
  14. In vivo mechanism of the "Bystander Effect, 2nd European Conference on Gene Therapy of Cancer, London, U.K., 1995.
  15. Enhanced tumor recognition and killing using the HSV-tk suicide gene, 4th International Symposium on Gene Therapy, San Diego, California, 1995.
  16. Tumor host interaction: Analysis of cytokines, growth factors and tumor infiltrating lymphocytes in ovarian carcinomas, FASEB Annual Meeting, New Orleans, Louisiana, June 2-6, 1996.
  17. Evaluation of adenovirus p53 mediated "Bystander Effect", 88th Annual Meeting of the American Association for Cancer Research, San Diego, California, 1997.
  18. Potentiation of the "Bystander Effect" by immunization combined with suicide gene therapy, 3rd European Conference on Gene Therapy of Cancer, Berlin, Germany, September 11-13, 1997.
  19. Evaluation of adenovirus p53 mediated bystander effect, 6th International Conference on Gene Therapy of Cancer, San Diego, California, November 20-22, 1997.
  20. Tumor killing using the HSV-tk suicide gene, 6th International Conference on Gene Therapy of Cancer, San Diego, California, November 20-22, 1997.
  21. Non-Viral Vectors for the treatment of disease, Keystone Symposium on Gene Therapy, Keystone, CO, February 1999.
  23. Non-Viral Vectors for the treatment of disease, Nature Biotechnology's Gene Therapy: Delivering the Medicines of the 21st century, Washington D.C., November 1999.
  24. Ad-MDA7: A novel, potent, and broad spectrum anti-tumor agent, European Gene Therapy Society, Stockholm, Sweden, October 2000. 26. Ad-MDA7: A novel, potent, and broad-spectrum anti-tumor agent, 7th International Symposium on Gene Therapy of Cancer, San Diego, California, December 2000.

Back to Top

Other Activities:

Local presentations:

  1. Suicide Gene Therapy and Mechanism of "Bystander Effect", Baylor Institute of Immunology, Dallas, Texas, April 15,1996.
  2. HSV-tk Mediated Bystander Effect: From Bench to Bedside, Introgen Therapeutics Inc., Houston, Texas, October 8, 1997.
  3. Novel Non-Viral Vector. W.M. Keck Foundation Presentation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, March 1999.
  4. Novel Non-viral Vector for Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, July 16, 1999.
  5. Inhibition of Solid and Disseminated Lung Tumors Following DOTAP: Cholesterol Liposome Mediated p53 Gene Delivery, Texas Medical Center Gene Therapy Symposium, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, September 1999.
  6. Novel Non-Viral Vector for Cancer Gene Therapy. Hematology Clinical Research Conference, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, November 4, 1999.
  7. Inhibition of Primary and Disseminated Lung Tumors by Systemic Delivery of DOTAP: Cholesterol-p53 Tumor Suppressor Gene, Introgen Therapeutics Inc., Houston, Texas, November 26, 1999.
  8. Adenovirus mediated mda-7 expression inhibits lung tumor growth, Introgen Therapeutics Inc., Houston, Texas, February 2000.
  9. Animal use in cancer gene therapy for lung cancer, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, October 13, 2000.
  10. Gene Therapeutic Approaches for Cancer Therapy, Health Science Technology Teachers/Texas Educational Agency, Houston, Texas, October 20, 2000.

Back to Top